


Atria

Consumer Goods
Finland


KEY DATA

Stock country	Finland
Bloomberg	ATRAV.FH
Reuters	ATRAV.HE
Share price (close)	EUR 10.25
Free float	42%
Market cap. (bn)	EUR 0.29/EUR 0.29
Website	www.atria.fi
Next report date	23 Oct 2024

PERFORMANCE



VALUATION APPROACH



Source: Nordea estimates

ESTIMATE CHANGES

Year	2024E	2025E	2026E
Sales	0%	0%	0%
EBIT (adj)	6%	4%	3%

Source: Nordea estimates

Nordea IB & Equity - Analysts

Joni Sandvall
Analyst

Strong performance set to continue

Atria's Q2 EBIT beat LSEG Data & Analytics consensus clearly. All divisions improved profitability, led by Finland, where the ramp-up of the new poultry unit has been completed without any surprises. Given its strong market position in Finland, we believe the company can continue to deliver in H2 and beyond, while improvement in Sweden could give further support to earnings growth. We raise our 2024-26 EBIT estimates by 3-6% and nudge up our DCF- and multiples-based fair value range to EUR 13.1-16.0 (12.9-15.7).

Q2 profitability clearly above expectations

Atria's Q2 EBIT of EUR 18.4m came in 47% above LSEG consensus and 28% above our estimate. Sales declined slightly y/y and were largely in line with expectations. The new poultry unit ramp-up has been successful, which, combined with increasing poultry demand, could support Finland's earnings growth, going forward. In Sweden, profitability improvement continues after the centralisation of production and changes in the organisational structure, while we note faster growth for the company than the market. In Estonia, strong performance continued, while in Denmark, we believe Atria needs higher volumes via a new production line in early 2025. After the large investment, the company is likely focusing on cash flows, while we see room for bolt-on acquisitions, especially in Sweden.

We raise 2024E-26E EBIT by 3-6%

After the Q2 beat, we raise 2024E-26E EBIT by 3-6%. We model an 18% adjusted EBIT increase for 2024 and a further 10% improvement in 2025, with support from the new poultry unit and improving performance in Sweden. Atria's guidance (raised on 12 July) is for its adjusted EBIT to improve in 2024. Trade tensions between the EU and China could have an impact on Atria's sales and profitability, though we note sales to China account for only about 1% of group sales based on our estimates.

Fair value range of EUR 13.1-16.0

Using our DCF- and multiples-based valuation methods, we derive a slightly higher fair value range of EUR 13.1-16.0 (12.9-15.7) per share. Following the completion of the new poultry unit and profit improvement measures in Sweden, we believe Atria is well positioned for a clear profitability uplift. After the investment period, cash flows are also likely to strengthen markedly, supporting increasing shareholder remuneration.

SUMMARY TABLE - KEY FIGURES

EURm	2020	2021	2022	2023	2024E	2025E	2026E
Total revenue	1,504	1,540	1,697	1,753	1,762	1,820	1,857
EBITDA (adj)	96	106	102	109	121	129	134
EBIT (adj)	40	49	49	50	59	65	69
EBIT (adj) margin	2.6%	3.2%	2.9%	2.8%	3.3%	3.5%	3.7%
EPS (adj, EUR)	0.91	0.97	1.54	1.04	1.11	1.32	1.48
EPS (adj) growth	51.8%	6.4%	58.7%	-32.5%	6.6%	18.7%	12.4%
DPS (ord, EUR)	0.50	0.63	0.70	0.60	0.65	0.72	0.77
EV/Sales	0.3	0.3	0.3	0.3	0.3	0.3	0.3
EV/EBIT (adj)	12.3	10.0	10.4	12.0	9.8	8.4	7.7
P/E (adj)	10.8	11.9	6.0	10.1	9.2	7.8	6.9
P/BV	0.7	0.7	0.6	0.8	0.7	0.7	0.7
Dividend yield (ord)	5.1%	5.5%	7.6%	5.7%	6.3%	7.0%	7.5%
FCF Yield bef A&D, lease	18.9%	7.2%	-31.1%	-8.4%	13.4%	18.5%	15.8%
Net debt	190	152	234	273	259	224	198
Net debt/EBITDA	2.0	2.4	2.2	2.7	2.1	1.7	1.5
ROIC after tax	4.8%	6.4%	6.3%	5.7%	6.6%	7.4%	7.9%

Source: Company data and Nordea estimates

Q2 deviation and estimate revisions

Q2 EBIT clearly beat consensus...

Strong Q2 profitability driven by all divisions

Atria reported Q2 adjusted EBIT of EUR 18.4m, 47% (EUR 5.9m) above LSEG Data & Analytics consensus. Q2 net sales of EUR 454m were down 1% y/y and came in 1% above consensus. The Q2 EBIT beat versus our estimate came from Finland and Sweden, while Denmark & Estonia was largely in line.

In Finland, sales declined due to lower feed sales and foodservice sales, while Q2 benefitted from a shift of export sales from Q1. Sweden profitability continued to improve, driven by the centralisation of production last year and a streamlining of the organisational structure. Fierce price competition in Denmark continued, while Estonia sales increased and profitability improved.

Operating cash flow was EUR 47m (EUR 45m a year ago).

...which led to higher guidance ahead of the report

Atria raised its guidance on 12 July and now expects 2024 adjusted EBITA to increase from EUR 49.6m in 2023 (earlier: "to decline"). Consensus has modelled a EUR 52.7m decline, i.e. -6%. The company notes risks related to a potential increase in tariffs for food exports to China.

Finland EBIT came in clearly above our expectations...

Atria Finland profitability clearly above our expectations

- Finland net sales of EUR 336m were down 3% y/y and came in 1% below our expectation. Net sales declined due to lower feed and foodservice sales, while export sales increased due to a shift from Q1.
- Adjusted EBIT was EUR 17.1m, 32% above our estimate of EUR 12.9m. Atria Finland benefitted from a favourable sales structure, a good start to the summer season, and savings and efficiency programmes. The closure of the old poultry unit in Sahalahti also supported earnings.
- Atria's supplier share remained stable.

...while Sweden's performance continued to improve

Atria Sweden back to growth mode – profitability above our expectations

- Sweden's net sales were EUR 94m, up 7% y/y and 6% above our estimate. Atria's market shares remained stable.
- Adjusted EBIT of EUR 1.6m was well above our estimate of EUR 1.1m.
- Atria Sweden benefitted from the centralisation of production at Sköllersta and the streamlining of the organisational structure.

Denmark took a step back due to lower volumes, while Estonia continued to grow

Atria Denmark & Estonia EBIT in line with our expectations

- Denmark & Estonia net sales were EUR 32m, up 2% y/y and 1% below our expectation. In Denmark, sales were weighed down by lower volumes for retail. In Estonia, the company continued to improve its market share with increasing sales to retail customers.
- Adjusted EBIT was EUR 1.5m, in line with our estimate.

DEVIATION TABLE

	Actual	NDA est.	Deviation		Consensus	Deviation		Actual	Actual		
EURm	Q2 2024	Q2 2024E	vs. actual		Q2 2024E	vs. actual		Q1 2024	q/q	Q2 2023	y/y
Sales	454	452	2	0%	450	4	1%	417	9%	457	-1%
Adj. EBIT	18.4	14.3	4.1	28%	12.5	5.9	47%	8.0	130%	9.9	86%
Adj. EBIT margin	4.1%	3.2%	0.9pp	0.9pp	2.8%	1.3pp		1.9%	2.1pp	2.2%	1.9pp
Adj. EPS, EUR	0.39	0.26	0.13	52%	0.23	0.16	72%	0.10	294%	0.13	190%
Divisional sales, EURm											
Finland	336.1	338.5	-2	-1%				310	8%	345	-3%
Sweden	93.8	88.2	6	6%				82	14%	88	7%
Denmark & Estonia	32.1	32.3	0	-1%				31	5%	31	2%
Unallocated	0.0	0.0	0	n.m.				0	n.m.	0	n.m.
Group eliminations	-7.7	-6.6	-1	17%				-6	33%	-7	4%
Group	454.3	452.4	1.9	0%				417	9%	457	-1%
Divisional adj. EBIT, EURm											
Finland	17.1	12.9	4.2	32%				7.2	138%	12.7	35%
Sweden	1.6	1.1	0.5	42%				0		-2.1	-176%
Denmark & Estonia	1.5	1.5	0.0	1%				1.4	7%	0.6	n.m.
Group eliminations	-1.7	-1.2	-0.5	42%				-0.6	183%	-1.3	31%
Group	18.4	14.3	4.1	28%				8	130%	9.9	86%

Source: Company data, LSEG Data & Analytics and Nordea estimates

2024 guidance was raised ahead of the report

Atria raised its guidance on 12 July, and now expects adjusted EBIT to increase in 2024 after EUR 49.6m in 2023 (earlier: "to decline"). Prior to the Q2 report, LSEG Data & Analytics consensus was for adjusted EBIT of EUR 52.7m in 2024, i.e. a 6% adjusted EBIT increase for 2024.

Trade tensions could have an adverse impact

Given the ongoing trade tensions between the EU and China, there are some risks related to Chinese exports, which could weaken the profitability of the Finnish operations if increased tariffs are introduced.

Estimate revisions

We forecast an 18% adjusted EBIT increase for 2024

Following the Q2 report, we leave our top-line estimates intact. We hike 2024E adjusted EBIT by 6% following the Q2 beat. For 2025E-26E, we nudge up adjusted EBIT by 3-4% and continue to expect a clear profitability uplift following the completion of the new poultry unit and turnaround actions in Sweden.

ESTIMATE REVISIONS AFTER THE Q1 REPORT (EURm; DPS IN EUR)

EURm	New estimates				Old estimates				Difference %			
	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E
Sales	437	1,762	1,820	1,857	441	1,767	1,826	1,862	-1%	0%	0%	0%
Adj. EBIT	17.1	58.7	64.6	68.7	17.2	55.3	61.8	66.9	-1%	6%	4%	3%
Adj. EBIT margin	3.9%	3.3%	3.5%	3.7%	3.9%	3.1%	3.4%	3.6%	0.0pp	0.2pp	0.2pp	0.1pp
Adj. EPS, EUR	0.34	1.11	1.32	1.48	0.35	1.04	1.26	1.45	-3%	7%	4%	2%
DPS		0.65	0.72	0.77		0.65	0.72	0.77		0%	0%	0%
Divisional sales EURm	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E
Finland	320	1,306	1,352	1,379	327	1,319	1,365	1,392	-2%	-1%	-1%	-1%
Sweden	90	355	367	375	87	346	358	365	3%	3%	3%	3%
Denmark & Estonia	33	127	129	131	33	128	129	132	-1%	-1%	-1%	-1%
Unallocated	0	0	0	0	0	0	0	0	nm.	nm.	nm.	nm.
Group eliminations	-7	-27	-28	-28	-7	-26	-26	-27	0%	4%	4%	4%
Group	437	1,762	1,820	1,857	441	1,767	1,826	1,862	-1%	0%	0%	0%
Divisional adj. EBIT	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E
Finland	14.8	53.1	57.2	60.4	14.9	49.5	54.8	58.6	-1%	7%	4%	3%
Sweden	2.0	5.2	7.0	7.8	1.9	4.6	5.8	6.9	9%	14%	21%	13%
Denmark & Estonia	1.6	5.3	5.5	5.6	1.6	5.4	5.6	5.7	-3%	-2%	-2%	-2%
Unallocated	-1.3	-4.9	-5.1	-5.2	-1.2	-4.2	-4.3	-4.4	8%	17%	17%	17%
Group	17.1	58.7	64.6	68.7	17.2	55.3	61.8	66.9	-1%	6%	4%	3%
Divisional sales growth	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E
Finland	-1%	-1%	3%	2%	1%	-1%	3%	2%	-2.0pp	-0.9pp	0.0pp	0.0pp
Sweden	12%	8%	3%	2%	9%	5%	3%	2%	3.4pp	2.8pp	0.0pp	0.0pp
Denmark & Estonia	2%	4%	1%	2%	3%	5%	1%	2%	-1.0pp	-0.7pp	0.0pp	0.0pp
Unallocated	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group eliminations	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group	2%	1%	3%	2%	3%	1%	3%	2%	-0.9pp	-0.3pp	0.0pp	0.0pp
EBIT margin	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E	Q3 2024E	2024E	2025E	2026E
Finland	4.6%	4.1%	4.2%	4.4%	4.5%	3.8%	4.0%	4.2%	0.1pp	0.3pp	0.2pp	0.2pp
Sweden	2.2%	1.5%	1.9%	2.1%	2.1%	1.3%	1.6%	1.9%	0.1pp	0.1pp	0.3pp	0.2pp
Denmark & Estonia	4.9%	4.2%	4.3%	4.3%	5.0%	4.2%	4.3%	4.4%	-0.1pp	-0.1pp	-0.1pp	0.0pp
Unallocated	nm.	nm.	nm.	nm.	nm.	nm.	nm.	nm.	nm.	nm.	nm.	nm.
Group	3.9%	3.3%	3.5%	3.7%	3.9%	3.1%	3.4%	3.6%	0.0pp	0.2pp	0.2pp	0.1pp

Source: Nordea estimates

Valuation

We derive a fair value range based on the combination of a DCF model and relative multiples. In our relative valuation, we compare Atria to companies that we consider its most relevant European peers using various metrics. Based on these methods, we derive a fair value range of EUR 13.1-16.0(12.9-15.7) per share for Atria.

DCF valuation yields EUR 14.1-17.2 per share

The outcome of our DCF valuation is EUR 14.1-17.2 per share. We use a WACC of 7.4-8.3%, assuming a terminal growth rate of 1.5% and an EBIT margin of 3%.

WACC COMPONENTS	
WACC components	
Risk-free interest rate	3.5%
Market risk premium	4.0%
Equity beta	1.3-1.6
Cost of equity	8.8-10.0%
Cost of debt	4.0%
Tax-rate used in WACC	20%
Equity weight	75%
WACC	7.4-8.3%

Source: Nordea estimates

DCF VALUE (EURm AND EUR)		
DCF value	Value	Per share
NPV FCFF	671-759	23.7-26.9
(Net debt)	-273	-9.7
Market value of associates	0	0.0
(Market value of minorities)	-22	-0.8
Surplus values	0	0.0
(Market value preference shares)	0	0.0
Share based adjustments	0	0.0
Other adjustments	0	0.0
Time value	22	0.8
DCF Value	397-486	14.1-17.2


Source: Nordea estimates

DCF ASSUMPTIONS

Averages and assumptions	2024-29	2030-34	2035-39	2040-44	2045-49	2050-54	Sust.
Sales growth, CAGR	2.3%	1.5%	1.5%	1.5%	1.5%	1.5%	
EBIT-margin, excluding associate	3.7%	3.0%	3.0%	3.0%	3.0%	3.0%	2.0%
Capex/depreciation, x	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Capex/sales	3.4%	3.4%	3.4%	3.4%	3.4%	3.4%	
NWC/sales	-0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	
FCFF, CAGR	7.3%	-0.6%	1.5%	1.5%	1.5%	-7.3%	1.5%

Source: Nordea estimates

DCF VALUATION COMPOSITION



Source: Nordea estimates

DCF valuation sensitivity

To highlight the sensitivity of our DCF valuation, we also provide sensitivity matrices that model variations in revenue growth, margin assumptions and the cost of capital. The sensitivities in our WACC are outlined in the following tables.

When we use sensitivities to changes of ± 0.5 pp for WACC, ± 0.5 pp for sales growth, and ± 0.5 pp for the EBIT margin, our DCF model gives us a value range of EUR 12.1-19.5 per share.

SENSITIVITY OF OUR DCF MODEL (EUR)

Sensitivity analysis: WACC vs EBIT margin

		WACC				
		7.3%	7.5%	7.8%	8.0%	8.3%
EBIT marg. change	1.0pp	23.8	22.5	21.3	20.1	19.1
	0.5pp	20.6	19.5	18.4	17.5	16.6
	0.0pp	17.4	16.5	15.6	14.8	14.1
	-0.5pp	14.3	13.5	12.8	12.1	11.5
	-1.0pp	11.1	10.5	10.0	9.5	9.0

- A ± 0.5 pp sales growth change translates to a change of $\pm 5\%$ in the fair value

Sensitivity analysis: WACC vs Sales growth

		WACC				
		7.3%	7.5%	7.8%	8.0%	8.3%
Sales gr. change	1.0pp	19.5	18.4	17.4	16.5	15.6
	0.5pp	18.4	17.4	16.5	15.6	14.8
	0.0pp	17.4	16.5	15.6	14.8	14.1
	-0.5pp	16.5	15.6	14.8	14.1	13.4
	-1.0pp	15.7	14.9	14.1	13.4	12.7

- A ± 0.5 pp EBIT margin change translates into a change of $\pm 18\%$ in the fair value

Sensitivity analysis: Sales growth vs EBIT margin

		Sales growth change				
		-1.0pp	-0.5pp	+0.0pp	+0.5pp	+1.0pp
EBIT margin change	1.0pp	19.1	20.1	21.3	22.5	23.8
	0.5pp	16.6	17.5	18.4	19.5	20.6
	0.0pp	14.1	14.8	15.6	16.5	17.4
	-0.5pp	11.6	12.2	12.8	13.5	14.2
	-1.0pp	9.1	9.5	10.0	10.5	11.0

Source: Nordea estimates

Relative valuation versus European peers

We compare Atria to European food processing peers that we find relevant for the company. We derive an EV/EBIT valuation range of EUR 13.2-16.2 by taking 2024E adjusted EBIT of EUR 58.7m, multiplying it by the accepted multiple range of 10.8-12.2x and deducting our 2024 net debt assumption of EUR 259m (including IFRS 16 lease liabilities). We also derive a P/E valuation range of EUR 10.8-13.2, taking 2024E adjusted EPS of EUR 1.11 and multiplying it by an accepted multiple range of 10.8-13.2x.

PEER GROUP VALUATION MULTIPLES (x)

	Country	Price	Mcap	EV	EV/EBIT				P/E				Div yield %	
		Local	EURm	EURm	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E	2024E	2025E
European peers														
Apetit Oyj	Finland	13.9	87	82	10.7	10.2	11.7	11.7	8.9	12.3	13.5	13.6	5.4%	5.4%
Bell Food Group Ag	Switzerland	259.5	1,669	2,533	14.6	14.1	14.0	13.1	10.2	11.3	11.5	10.8	2.8%	2.7%
Cranswick Plc	UK	4,600.0	2,948	3,064	15.2	13.8	13.0	12.3	20.4	18.9	17.6	16.6	2.0%	2.1%
Hkfoods Oyj	Finland	0.7	63	297	10.6	15.2	12.6	11.9			15.1	8.5	0.0%	0.0%
Raisio Oyj	Finland	2.0	314	248	10.9	10.8	9.4	8.4	14.9	15.8	14.1	12.7	7.1%	7.1%
Scandi Standard Ab (Publ)	Sweden	73.6	420	569	14.4	12.9	11.7	9.8	18.0	16.0	13.9	10.8	3.6%	4.2%
Societe Ldc Sa	France	146.0	2,565	2,191	6.0	6.2	6.1	5.5	8.6	9.4	8.9	8.1	2.2%	2.2%
What'S Cooking Group Nv	Belgium	75.0	139	200	9.3		6.1	5.9	12.6	8.1	6.4	6.0	6.7%	6.7%
Average			1,026	1,148	11.5	11.9	10.6	9.8	13.4	13.1	12.6	10.9	3.7%	3.8%
Median			367	433	10.8	12.9	11.7	10.7	12.6	12.3	13.7	10.8	3.2%	3.5%
Atria (NDA)		10.2	287	560	11.3	9.3	7.9	7.1	10.1	9.2	7.7	6.9	6.4%	7.1%

Source: LSEG Data & Analytics and Nordea estimates (as of market close on 17 July)

PEER GROUP KEY FIGURES

	Sales growth				EBIT margin				ROE			
European peers	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E	2023	2024E	2025E	2026E
Apetit Oyj	-3.5%	-4.8%	3.6%	3.5%	4.3%	4.8%	4.0%	3.9%	9.8%	6.8%	6.1%	6.0%
Bell Food Group Ag	7.5%	2.9%	2.4%	2.3%	3.7%	3.7%	3.6%	3.8%	8.7%	8.5%	7.9%	8.6%
Cranswick Plc	13.5%	7.7%	4.9%	5.2%	6.9%	7.0%	7.1%	7.2%	13.1%	13.8%	13.5%	13.1%
Hkfoods Oyj	-4.6%	-48.1%	3.8%		1.5%	2.0%	2.3%	2.4%	-9.1%	-1.5%	2.3%	3.7%
Raisio Oyj	-1.4%	2.5%	5.3%	5.7%	10.4%	10.2%	11.2%	11.8%	6.7%	7.6%	8.7%	9.4%
Scandi Standard Ab (Put	-0.3%	-0.6%	4.1%	-2.1%	3.5%	4.0%	4.2%	5.1%	11.4%	12.0%	12.9%	15.0%
Societe Ldc Sa	8.0%	5.2%	4.7%	3.9%	6.0%	5.5%	5.3%	5.6%	14.8%	11.6%	10.8%	11.2%
What'S Cooking Group N	6.5%	2.7%	2.9%		2.6%	3.3%	3.7%	3.8%	6.3%	0.0%	0.0%	0.0%
Average	3.2%	-4.1%	4.0%	3.1%	4.9%	5.1%	5.2%	5.4%	7.7%	7.4%	7.8%	8.4%
Median	3.1%	2.6%	4.0%	3.7%	4.0%	4.4%	4.1%	4.5%	9.3%	8.1%	8.3%	9.0%
Atria (NDA)	3.3%	0.5%	3.3%	2.0%	2.8%	3.3%	3.5%	3.7%	-4.7%	7.9%	9.0%	9.7%


Source: LSEG Data & Analytics and Nordea estimates (as of market close on 17 July)

Valuation conclusion

From our DCF-based valuation and a relative multiples-based valuation, we derive a fair value range of EUR 13.1-16.0 (12.9-15.7) per Atria share, as shown by the red dotted lines in the chart below.

VALUATION (EUR)

Fair value range of
EUR 13.1-16.0



Source: Nordea estimates

Detailed estimates

ANNUAL ESTIMATES (EURm)

Income statement (EURm)	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Sales	1,352	1,436	1,439	1,451	1,504	1,540	1,697	1,753	1,762	1,820	1,857
- sales growth	0.9%	6.2%	0.2%	0.9%	3.6%	2.4%	10.2%	3.3%	0.5%	3.3%	2.0%
Gross profit	164	173	153	163	166	177	169	167	189	197	202
- margin	12.2%	12.1%	10.6%	11.2%	11.1%	11.5%	9.9%	9.6%	10.8%	10.8%	10.9%
EBITDA	79	87	74	85	96	64	104	100	121	129	134
- margin	5.8%	6.1%	5.1%	5.9%	6.4%	4.1%	6.1%	5.7%	6.9%	7.1%	7.2%
D&A	-47	-46	-45	-54	-57	-57	-104	-100	-62	-65	-66
EBIT reported	31.8	40.9	28.2	31.1	39.5	6.4	0.2	0.3	58.7	64.6	68.7
Adj. EBIT	31.2	39.6	28.2	33.0	40.3	49.2	49.0	49.5	58.7	64.6	68.7
- margin	2.3%	2.8%	2.0%	2.3%	2.7%	3.2%	2.9%	2.8%	3.3%	3.5%	3.7%
Net finance	-6	-7	-6	-6	-5	-5	-3	-14	-16	-14	-11
Associated companies	1	2	0	1	1	3	5	2	1	2	2
Adj. PTP	25.7	34.1	22.3	28.2	36.1	47.6	50.6	38.1	44.2	53.1	59.7
Taxes	-6.6	-7.1	-4.5	-9.2	-12.6	-10.2	-5.5	-4.2	-8.4	-10.6	-11.9
Profit before minorities	19.6	28.4	17.8	17.0	23.5	-5.4	-3.7	-15.3	35.8	42.5	47.8
Minorities	-1.4	-2.5	-1.4	-1.9	-1.8	-1.5	-1.5	-4.5	-4.5	-5.3	-6.0
Adj. Net Profit	17.8	24.5	16.5	17.0	25.8	27.4	43.6	29.4	31.3	37.2	41.8
EPS, excluding NRI (EUR)	0.63	0.87	0.59	0.60	0.91	0.97	1.54	1.04	1.11	1.32	1.48
Divisional sales EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Finland	932	986	1,019	1,034	1,066	1,106	1,265	1,326	1,306	1,352	1,379
Sweden		307	288	289	332	352	356	331	355	367	375
Denmark & Estonia		99	98	97	107	105	113	122	127	129	131
Unallocated	72	86	75	74	52	15	0	0	0	0	0
Group eliminations	-30	-42	-41	-42	-53	-37	-38	-26	-27	-28	-28
Group	1,352	1,436	1,439	1,451	1,504	1,540	1,697	1,753	1,762	1,820	1,857
Divisional operative EBIT	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Finland	24.2	36.3	36.7	40.0	43.1	48.1	49.4	56.0	53.1	57.2	60.4
Sweden		1.0	-7.1	-4.6	0.8	2.7	2.3	-5.7	5.2	7.0	7.8
Denmark & Estonia		5.2	5.3	4.3	5.2	5.1	1.3	2.9	5.3	5.5	5.6
Unallocated	-0.9	-3.8	-2.7	-3.1	-8.8	-6.9	-4.0	-3.7	-4.9	-5.1	-5.2
Group	31.4	39.5	28.2	33.1	39.5	49.2	49.0	49.5	58.7	64.6	68.7
Divisional sales growth	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Finland	0%	6%	3%	1%	3%	4%	14%	5%	-1%	3%	2%
Sweden		n.a.	-6%	0%	15%	6%	1%	-7%	8%	3%	2%
Denmark & Estonia		n.a.	-1%	-1%	11%	-2%	8%	8%	4%	1%	2%
Unallocated	-4%	19%	-12%	-2%	-30%	-72%	n.m.	n.m.	n.m.	n.m.	n.m.
Group eliminations	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group	1%	6%	0%	1%	4%	2%	10%	3%	1%	3%	2%
EBIT margin	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Finland	2.6%	3.7%	3.6%	3.9%	4.0%	4.4%	3.9%	4.2%	4.1%	4.2%	4.4%
Sweden		0.3%	-2.5%	-1.6%	0.2%	0.8%	0.6%	-1.7%	1.5%	1.9%	2.1%
Denmark & Estonia		5.3%	5.4%	4.5%	4.9%	4.9%	1.2%	2.4%	4.2%	4.3%	4.3%
Group eliminations	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group	2.3%	2.8%	2.0%	2.3%	2.6%	3.2%	2.9%	2.8%	3.3%	3.5%	3.7%

Source: Company data and Nordea estimates

QUARTERLY ESTIMATES (EURm)

Income statement (EURm)	Q1/22	Q2/22	Q3/22	Q4/22	Q1/23	Q2/23	Q3/23	Q4/23	Q1/24	Q2/24	Q3/24E	Q4/24E
Sales	375	432	439	451	428	457	430	438	417	454	437	455
- sales growth	3.7%	11.5%	13.1%	11.8%	14.2%	5.9%	-2.1%	-2.9%	-2.6%	-0.6%	1.7%	3.8%
Gross profit	31.6	46.5	41.9	48.7	42.0	41.6	45.0	38.8	38.4	52.2	48.9	49.9
- margin	8.4%	10.8%	9.5%	10.8%	9.8%	9.1%	10.5%	8.9%	9.2%	11.5%	11.2%	11.0%
EBITDA	15.8	28.9	29.4	30.0	23.8	23.1	34.4	18.9	23.0	33.5	33.1	32.0
- margin	4.2%	6.7%	6.7%	6.6%	5.6%	5.1%	8.0%	4.3%	5.5%	7.4%	7.6%	7.0%
D&A	-14	-13	-13	-65	-13	-13	-15	-59	-15	-15	-16	-16
EBIT reported	2.3	15.9	16.5	-34.5	10.9	9.9	19.4	-39.9	8.0	18.5	17.1	15.8
Adj. EBIT	2.3	13.8	16.2	16.7	10.9	9.9	19.4	9.3	8.0	18.5	17.1	15.8
- margin	0.6%	3.2%	3.7%	3.7%	2.5%	2.2%	4.5%	2.1%	1.9%	4.1%	3.9%	3.5%
Net finance	-0.9	-0.7	-0.3	-1.5	-3.2	-3.7	-3.2	-3.5	-4.2	-4.2	-3.8	-3.3
Associated companies	1.4	2.1	2.2	-0.8	1.1	0.5	0.8	-0.3	0.1	0.3	0.2	0.4
Adj. PTP	2.9	15.2	18.1	14.4	8.9	6.7	17.0	5.5	3.9	14.6	13.5	12.9
Taxes	-0.2	-3.1	-2.4	0.2	-2.0	-1.6	-2.4	1.8	-0.1	-2.6	-2.7	-3.0
Profit before minorities	2.7	14.2	16.0	-36.6	6.9	5.1	14.6	-41.9	3.8	12.0	10.8	9.9
Minorities	-0.2	-0.6	0.5	-1.2	-0.5	-1.3	-1.4	-1.3	-1.0	-1.0	-1.3	-1.2
Adj. Net Profit	2.5	11.5	16.2	13.4	6.4	3.8	13.2	6.0	2.8	11.0	9.5	8.7
EPS, excluding NRI (EUR)	0.09	0.41	0.57	0.47	0.23	0.13	0.47	0.21	0.10	0.39	0.34	0.31
Divisional sales EURm	Q1/22	Q2/22	Q3/22	Q4/22	Q1/23	Q2/23	Q3/23	Q4/23	Q1/24	Q2/24	Q3/24E	Q4/24E
Finland	274	320	327	344	324	345	324	334	310	336	320	340
Sweden	82	95	93	86	82	88	81	80	82	94	90	89
Denmark & Estonia	26	28	29	29	28	31	32	31	31	32	33	32
Unallocated	0	0	0	0	0	0	0	0	0	0	0	0
Group eliminations	-8	-11	-10	-9	-6	-7	-7	-7	-6	-8	-7	-7
Group	375	432	439	451	428	457	430	438	417	454	437	455
Divisional operative EBIT	Q1/22	Q2/22	Q3/22	Q4/22	Q1/23	Q2/23	Q3/23	Q4/23	Q1/24	Q2/24	Q3/24E	Q4/24E
Finland	3.0	13.4	12.7	20.3	14.9	12.7	19.0	9.4	7.2	17.1	14.8	14.0
Sweden	-0.9	0.7	3.4	-0.9	-3.3	-2.1	0.0	-0.3	0.0	1.6	2.0	1.6
Denmark & Estonia	0.8	0.7	0.7	-0.9	-0.5	0.6	1.5	1.3	1.4	1.5	1.6	1.5
Unallocated	-0.6	-1.0	-0.6	-1.8	-0.2	-1.3	-1.1	-1.1	-0.6	-1.7	-1.3	-1.3
Group	2.3	13.8	16.2	16.7	10.9	9.9	19.4	9.3	8.0	18.5	17.1	15.8
Divisional sales growth	Q1/22	Q2/22	Q3/22	Q4/22	Q1/23	Q2/23	Q3/23	Q4/23	Q1/24	Q2/24	Q3/24E	Q4/24E
Finland	5%	15%	19%	17%	18%	8%	-1%	-3%	-4%	-3%	-1%	2%
Sweden	7%	8%	-2%	-7%	0%	-8%	-13%	-7%	0%	7%	12%	11%
Denmark & Estonia	6%	6%	7%	11%	8%	11%	10%	4%	9%	2%	2%	4%
Unallocated	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group eliminations	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group	4%	12%	13%	12%	14%	6%	-2%	-3%	-3%	-1%	2%	4%
EBIT margin	Q1/22	Q2/22	Q3/22	Q4/22	Q1/23	Q2/23	Q3/23	Q4/23	Q1/24	Q2/24	Q3/24E	Q4/24E
Finland	1.1%	4.2%	3.9%	5.9%	4.6%	3.7%	5.9%	2.8%	2.3%	5.1%	4.6%	4.1%
Sweden	-1.1%	0.7%	3.7%	-1.0%	-4.0%	-2.4%	0.0%	-0.4%	0.0%	1.7%	2.2%	1.8%
Denmark & Estonia	3.1%	2.5%	2.4%	-3.1%	-1.8%	1.9%	4.7%	4.2%	4.6%	4.7%	4.9%	4.6%
Group eliminations	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Group	0.6%	3.2%	3.7%	3.7%	2.5%	2.2%	4.5%	2.1%	1.9%	4.1%	3.9%	3.5%

Source: Company data and Nordea estimates

Risk factors

In this section, we highlight the main risks that we find relevant for Atria. We list risks according to their relevance, with the most relevant on top. The following is not an exhaustive list but rather our view of some key risks for the company.

Increasing raw material prices

Atria's profitability depends on changes in global market prices for meat raw materials, which affect Atria on a lag. Because Atria and other meat processing companies are in the middle of the value chain, it might be difficult to fully implement the product price hikes needed to protect EBIT margins in the event of elevated meat raw material prices. The annual harvest might have indirect impacts on meat raw material prices. Current geopolitical tensions could also have a negative impact on the availability of materials such as fertilisers, which could increase grain prices, and hence meat raw material prices even further.

Changes in customer demand

Atria's key market areas of retail trade are highly centralised, making it dependent on individual customers. Shifts in consumer demand could thus affect Atria's margins.

Outbreak of animal diseases

Animal disease discovered at a critical point in Atria's production chain could interrupt production in the unit concerned and disrupt operations throughout the chain. The development of African swine fever (ASF) could cause similar restrictions and government guidance pressure, much as avian influenza did in Sweden in H2 2017. Diseases may even lead to import and export restrictions on meat products. The latest outbreak of ASF in Sweden causes additional uncertainty, although it does not have a direct impact on Atria as the company does not have significant export business in the country. An outbreak of animal diseases in Atria's operating countries, especially in Finland, could have a substantial effect on its short-term sales and profits.

Changes in consumer demand

In the long term, consumer behaviour may change the pattern of demand for Atria's products across different categories. As a result, shifts in consumer demand could affect Atria's net sales and eventually its margins.

Operational disturbances

Atria has production plants in Finland, Sweden, Denmark and Estonia. Its operations are process-centric and disturbances in a critical part of the process could result in the suspension of plant operations.

Product safety issues

As a food manufacturing company, Atria is exposed to internal and external quality and safety issues throughout the production chain. Product safety issues may hamper Atria's reputation as a quality producer.

Financial risks

The key financial risks are translation, transaction and refinancing risks. Atria's main transaction and translation risks are in its Swedish operations. In addition, given higher interest rates, we note risks related to possible writedowns of accounts receivable, e.g. if foodservice customers were to face liquidity issues.

Goodwill

Atria has EUR 83m of goodwill on its balance sheet. If there were operational challenges, it could have to make an impairment to its assets. Following writedowns in Denmark and Sweden, the risk of writedowns has decreased, in our view. In the event of possible writedowns, there should only be a limited impact on Atria's balance sheet, however, and an impairment would not have any cash flow impact.

Increasing competition from foreign products

Atria primarily uses domestic meat raw materials, and domestic customers demand mostly domestic meat products. In a scenario with changes in demand and foreign competitors entering the market, increased competition could affect profitability. In addition, we note an increasing share of private-label products, which could be imported and put pressure on the pricing of branded products and domestically produced private-label products.

Reported numbers and forecasts

INCOME STATEMENT

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Total revenue	1,352	1,436	1,439	1,451	1,504	1,540	1,697	1,753	1,762	1,820	1,857
Revenue growth	0.9%	6.2%	0.2%	0.9%	3.6%	2.4%	10.2%	3.3%	0.5%	3.3%	2.0%
of which organic	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
of which FX	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
EBITDA	79	87	74	85	96	64	104	100	121	129	134
Depreciation and impairments PPE	-47	-46	-45	-54	-57	-57	-104	-100	-62	-65	-66
of which leased assets	0	0	0	-9	-9	-9	-9	-9	-5	-5	-5
EBITA	32	41	28	31	40	6	0	0	59	65	69
Amortisation and impairments	0	0	0	0	0	0	0	0	0	0	0
EBIT	32	41	28	31	40	6	0	0	59	65	69
of which associates	0	0	0	0	0	0	0	0	0	0	0
Associates excluded from EBIT	1	2	0	1	1	3	5	2	1	2	2
Net financials	-6	-7	-6	-6	-5	-5	-3	-14	-16	-14	-11
of which lease interest	0	0	0	0	0	0	0	0	0	0	0
Changes in value, net	0	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	26	36	22	26	36	5	2	-11	44	53	60
Reported taxes	-7	-7	-5	-9	-13	-10	-6	-4	-8	-11	-12
Net profit from continued operations	20	28	18	17	24	-5	-4	-15	36	42	48
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0
Minority interests	-1	-3	-1	-2	-2	-2	-2	-5	-4	-5	-6
Net profit to equity	18	26	17	15	22	-7	-5	-20	31	37	42
EPS, EUR	0.65	0.92	0.59	0.53	0.77	-0.24	-0.19	-0.70	1.11	1.32	1.48
DPS, EUR	0.46	0.50	0.40	0.42	0.50	0.63	0.70	0.60	0.65	0.72	0.77
of which ordinary	0.46	0.50	0.40	0.42	0.50	0.63	0.70	0.60	0.65	0.72	0.77
of which extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Profit margin in percent

EBITDA	5.8%	6.1%	5.1%	5.9%	6.4%	4.1%	6.1%	5.7%	6.9%	7.1%	7.2%
EBITA	2.3%	2.8%	2.0%	2.1%	2.6%	0.4%	0.0%	0.0%	3.3%	3.5%	3.7%
EBIT	2.3%	2.8%	2.0%	2.1%	2.6%	0.4%	0.0%	0.0%	3.3%	3.5%	3.7%

Adjusted earnings

EBITDA (adj)	78	86	74	87	96	106	102	109	121	129	134
EBITA (adj)	31	40	28	33	40	49	49	50	59	65	69
EBIT (adj)	31	40	28	33	40	49	49	50	59	65	69
EPS (adj, EUR)	0.63	0.87	0.59	0.60	0.91	0.97	1.54	1.04	1.11	1.32	1.48

Adjusted profit margins in percent

EBITDA (adj)	5.8%	6.0%	5.1%	6.0%	6.4%	6.9%	6.0%	6.2%	6.9%	7.1%	7.2%
EBITA (adj)	2.3%	2.8%	2.0%	2.3%	2.6%	3.2%	2.9%	2.8%	3.3%	3.5%	3.7%
EBIT (adj)	2.3%	2.8%	2.0%	2.3%	2.6%	3.2%	2.9%	2.8%	3.3%	3.5%	3.7%

Performance metrics

CAGR last 5 years											
Net revenue	0.8%	1.3%	0.4%	0.4%	2.3%	2.6%	3.4%	4.0%	4.0%	3.9%	3.8%
EBITDA	7.2%	1.8%	-6.2%	-1.0%	7.1%	-4.2%	3.7%	6.4%	7.2%	6.1%	16.1%
EBIT	31.9%	6.2%	7.4%	-5.2%	6.4%	-27.4%	-65.5%	-59.7%	13.5%	10.3%	60.7%
EPS	n.m.	21.3%	n.m.	-10.6%	9.4%	n.m.	n.m.	n.m.	15.9%	11.4%	n.m.
DPS	18.1%	17.8%	12.7%	1.0%	4.6%	6.5%	7.0%	8.4%	9.1%	7.6%	4.1%
Average last 5 years											
Average EBIT margin	2.2%	2.3%	2.4%	2.3%	2.4%	2.0%	1.4%	1.0%	1.3%	1.5%	2.2%
Average EBITDA margin	6.1%	6.1%	5.7%	5.6%	5.9%	5.5%	5.5%	5.7%	5.9%	6.0%	6.6%

VALUATION RATIOS - ADJUSTED EARNINGS

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
P/E (adj)	18.2	13.9	11.2	16.7	10.8	11.9	6.0	10.1	9.2	7.8	6.9
EV/EBITDA (adj)	7.0	6.6	5.7	6.0	5.0	4.6	5.0	5.4	4.8	4.2	3.9
EV/EBITA (adj)	17.5	14.3	14.9	15.7	12.3	10.0	10.4	12.0	9.8	8.4	7.7
EV/EBIT (adj)	17.5	14.3	14.9	15.7	12.3	10.0	10.4	12.0	9.8	8.4	7.7

VALUATION RATIOS - REPORTED EARNINGS

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
P/E	17.8	13.2	11.2	18.9	12.8	n.m.	n.m.	n.m.	9.2	7.8	6.9
EV/Sales	0.41	0.39	0.29	0.36	0.32	0.32	0.30	0.34	0.33	0.30	0.28
EV/EBITDA	7.0	6.5	5.7	6.1	5.0	7.7	4.9	5.9	4.8	4.2	3.9
EV/EBITA	17.3	13.8	14.9	16.8	12.3	76.6	2,554.2	1,976.9	9.8	8.4	7.7
EV/EBIT	17.3	13.8	14.9	16.8	12.3	76.6	2,554.2	1,976.9	9.8	8.4	7.7
Dividend yield (ord.)	4.0%	4.1%	6.1%	4.2%	5.1%	5.5%	7.6%	5.7%	6.3%	7.0%	7.5%
FCF yield	-0.8%	5.6%	1.0%	17.1%	20.8%	19.2%	-18.6%	-5.4%	12.7%	20.4%	17.7%
FCF Yield bef A&D, lease adj	6.9%	3.3%	1.5%	14.0%	18.9%	7.2%	-31.1%	-8.4%	13.4%	18.5%	15.8%
Payout ratio	72.8%	57.6%	68.3%	69.8%	54.8%	64.9%	45.4%	57.7%	58.6%	54.7%	52.1%

Source: Company data and Nordea estimates

BALANCE SHEET

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
Intangible assets	263	256	249	246	249	240	179	135	137	137	137
of which R&D	0	0	0	0	0	0	0	0	0	0	0
of which other intangibles	94	89	87	85	84	78	54	54	54	54	54
of which goodwill	170	167	163	161	165	163	125	81	84	84	84
Tangible assets	405	409	401	423	421	408	489	556	554	550	550
of which leased assets	0	0	0	30	25	22	21	19	19	19	19
Shares associates	14	15	15	15	15	17	20	20	21	23	25
Interest bearing assets	1	1	1	1	1	1	1	1	1	1	1
Deferred tax assets	7	6	5	4	2	2	1	2	2	2	2
Other non-IB non-current assets	11	9	10	5	5	6	18	10	10	10	10
Other non-current assets	0	0	0	0	0	0	0	0	0	0	0
Total non-current assets	701	696	681	694	692	674	708	724	726	724	726
Inventory	90	93	106	110	103	110	153	129	132	127	130
Accounts receivable	109	114	105	107	106	108	135	116	116	120	123
Short-term leased assets	0	0	0	9	9	9	9	5	5	5	5
Other current assets	5	4	3	4	4	4	4	5	5	5	5
Cash and bank	5	3	4	4	27	57	31	10	34	40	35
Total current assets	208	214	219	235	248	288	332	265	293	298	298
Assets held for sale	0	0	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Total assets	909	910	900	929	940	961	1,040	989	1,019	1,021	1,024
Shareholders equity	410	419	415	420	423	455	449	389	403	422	444
Of which preferred stocks	0	0	0	0	0	0	0	0	0	0	0
Of which equity part of hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Minority interest	12	12	13	14	16	13	15	22	27	32	38
Total Equity	422	431	428	434	439	468	464	411	430	454	482
Deferred tax	49	47	43	41	39	37	36	33	33	33	33
Long term interest bearing debt	178	122	153	141	139	176	232	256	266	236	206
Pension provisions	7	6	6	7	7	7	5	5	5	5	5
Other long-term provisions	0	0	0	1	0	0	1	1	1	1	1
Other long-term liabilities	11	8	7	7	2	3	7	6	6	6	6
Non-current lease debt	0	0	0	25	25	21	21	15	20	20	20
Convertible debt	0	0	0	0	0	0	0	0	0	0	0
Shareholder debt	0	0	0	0	0	0	0	0	0	0	0
Hybrid debt	0	0	0	0	0	0	0	0	0	0	0
Total non-current liabilities	245	184	209	221	212	245	302	316	331	301	271
Short-term provisions	0	0	0	0	0	0	0	0	0	0	0
Accounts payable	200	202	188	211	234	237	261	249	250	258	263
Current lease debt	0	0	0	9	10	10	10	10	5	5	5
Other current liabilities	3	1	0	0	0	0	0	0	0	0	0
Short term interest bearing debt	40	92	75	54	45	3	3	3	3	3	3
Total current liabilities	242	295	262	274	289	249	274	261	258	266	272
Liabilities for assets held for sale	0	0	0	0	0	0	0	0	0	0	0
Total liabilities and equity	909	910	900	929	940	961	1,040	989	1,019	1,021	1,024
Balance sheet and debt metrics											
Net debt	212	210	222	223	190	152	234	273	259	224	198
of which lease debt	0	0	0	34	34	31	31	25	25	25	25
Working capital	1	7	27	10	-21	-15	31	1	4	-5	-6
Invested capital	703	703	708	705	670	659	739	725	729	718	720
Capital employed	640	645	656	663	657	678	730	696	725	719	716
ROE	4.5%	6.2%	4.0%	3.6%	5.2%	-1.6%	-1.2%	-4.7%	7.9%	9.0%	9.7%
ROIC	3.8%	4.8%	3.3%	3.8%	4.8%	6.4%	6.3%	5.7%	6.6%	7.4%	7.9%
ROCE	5.1%	6.4%	4.4%	5.1%	6.2%	7.9%	7.7%	7.2%	8.4%	9.2%	9.9%
Net debt/EBITDA	2.7	2.4	3.0	2.6	2.0	2.4	2.2	2.7	2.1	1.7	1.5
Interest coverage	5.0	5.6	4.5	5.6	8.8	1.3	0.1	0.0	3.8	4.8	6.2
Equity ratio	45.1%	46.0%	46.2%	45.2%	45.0%	47.3%	43.2%	39.3%	39.6%	41.3%	43.3%
Net gearing	50.3%	48.7%	51.9%	51.3%	43.4%	32.5%	50.3%	66.4%	60.2%	49.3%	41.2%

Source: Company data and Nordea estimates

CASH FLOW STATEMENT

EURm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E
EBITDA (adj) for associates	79	87	74	85	96	64	104	100	121	129	134
Paid taxes	-6	-10	-1	-9	-9	-15	-7	-11	-8	-11	-12
Net financials	-4	-8	-6	-6	-5	-2	-3	-14	-16	-14	-11
Change in provisions	0	-1	0	1	0	-1	-1	0	0	0	0
Change in other LT non-IB	5	1	0	5	-2	-1	-7	6	0	0	0
Cash flow to/from associates	0	0	0	0	0	0	0	0	0	0	0
Dividends paid to minorities	0	0	0	0	0	0	0	0	0	0	0
Other adj to reconcile to cash flow	-16	-10	-6	-6	-10	50	15	-20	0	0	0
Funds from operations (FFO)	58	59	60	71	71	94	100	62	97	105	111
Change in NWC	7	6	-13	17	31	-6	-46	31	-3	9	0
Cash flow from operations (CFO)	65	65	47	89	102	88	54	93	94	114	111
Capital expenditure	-43	-53	-45	-40	-41	-56	-126	-110	-50	-55	-60
Free cash flow before A&D	22	11	3	48	61	32	-73	-16	44	59	51
Proceeds from sale of assets	6	8	-1	0	0	30	28	1	2	0	0
Acquisitions	-30	0	0	0	-3	0	-4	0	-10	0	0
Free cash flow	-2	19	2	48	58	63	-49	-16	37	59	51
Free cash flow bef A&D, lease adj	22	11	3	40	53	24	-81	-25	39	54	46
Dividends paid	-11	-13	-15	-12	-12	-15	-19	-21	-17	-18	-20
Equity issues / buybacks	0	0	0	0	0	0	0	0	0	0	0
Net change in debt	15	-3	13	-40	-13	-5	48	24	10	-30	-30
Other financing adjustments	0	0	0	0	-9	-10	-9	-11	-6	-5	-5
Other non-cash adjustments	-1	-4	1	4	-2	-3	2	2	0	0	0
Change in cash	0	-1	1	0	22	31	-26	-21	24	5	-4
Cash flow metrics											
Capex/D&A	90.9%	n.m.	98.0%	73.8%	72.0%	97.7%	n.m.	n.m.	n.m.	n.m.	n.m.
Capex/Sales	3.2%	3.7%	3.1%	2.8%	2.7%	3.6%	7.4%	6.2%	2.8%	3.0%	3.2%
Key information											
Share price year end (/current)	11	12	7	10	10	12	9	11	10	10	10
Market cap.	324	341	185	284	278	326	262	297	290	290	290
Enterprise value	548	563	420	521	485	490	511	593	576	546	526
Diluted no. of shares, year-end (m)	28.2	28.2	28.2	28.3	28.3	28.3	28.3	28.3	28.3	28.3	28.3

Source: Company data and Nordea estimates

Disclaimer and legal disclosures

Origin of the report

This publication or report originates from: Nordea Bank Abp, including its branches Nordea Danmark, Filial af Nordea Bank Abp, Finland, Nordea Bank Abp, filial i Norge and Nordea Bank Abp, filial i Sverige (together "Nordea") acting through their units Nordea Markets and Equity Sales & Research.

Nordea Bank Abp is supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the branches are supervised by the European Central Bank and the Finnish Financial Supervisory Authority and the Financial Supervisory Authorities in their respective countries.

Content of report

This report has been prepared solely by Nordea Markets or Equity Sales & Research.

Opinions or suggestions from Nordea Markets credit and equity research may deviate from one another or from opinions presented by other departments in Nordea. This may typically be the result of differing time horizons, methodologies, contexts or other factors.

The information provided herein is not intended to constitute and does not constitute investment advice nor is the information intended as an offer or solicitation for the purchase or sale of any financial instrument. The information contained herein has no regard to the specific investment objectives, the financial situation or particular needs of any particular recipient. Relevant and specific professional advice should always be obtained before making any investment or credit decision.

Opinions or ratings are based on one or more methods of valuation, for instance cash flow analysis, use of multiples, behavioural technical analyses of underlying market movements in combination with considerations of the market situation and the time horizon. Key assumptions of forecasts or ratings in research cited or reproduced appear in the research material from the named sources. The date of publication appears from the research material cited or reproduced. Opinions and estimates may be updated in subsequent versions of the report, provided that the relevant company/issuer is treated anew in such later versions of the report.

Validity of the report

All opinions and estimates in this report are, regardless of source, given in good faith, and may only be valid as of the stated date of this report and are subject to change without notice.

No individual investment or tax advice

The report is intended only to provide general and preliminary information to investors and shall not be construed as the basis for any investment decision. This report has been prepared by Nordea Markets or Equity Sales & Research as general information for private use of investors to whom the report has been distributed, but it is not intended as a personal recommendation of particular financial instruments or strategies and thus it does not provide individually tailored investment advice, and does not take into account the individual investor's particular financial situation, existing holdings or liabilities, investment knowledge and experience, investment objective and horizon or risk profile and preferences. The investor must particularly ensure the suitability of an investment as regards his/her financial and fiscal situation and investment objectives. The investor bears the risk of losses in connection with an investment.

Before acting on any information in this report, it is recommendable to consult (without being limited to) one's financial, legal, tax, accounting, or regulatory advisor in any relevant jurisdiction.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. Each investor shall make his/her own appraisal of the tax and other financial merits of his/her investment.

Sources

This report may be based on or contain information, such as opinions, estimates and valuations which emanate from: Nordea Markets' or Equity Sales & Research analysts or representatives, publicly available information, information from other units of Nordea, or other named sources.

To the extent this publication or report is based on or contain information emanating from other sources ("Other Sources") than Nordea Markets or Equity Sales & Research ("External Information"), Nordea Markets or Equity Sales & Research has deemed the Other Sources to be reliable but neither Nordea, others associated or affiliated with Nordea nor any other person, do guarantee the accuracy, adequacy or completeness of the External Information.

Limitation of liability

Nordea or other associated and affiliated companies assume no liability as regards to any investment, divestment or retention decision taken by the investor on the basis of this report. In no event will Nordea or other associated and affiliated companies be liable for direct, indirect or incidental, special or consequential damages (regardless of whether being considered as foreseeable or not) resulting from the information in this report.

Risk information

The risk of investing in certain financial instruments, including those mentioned in this report, is generally high, as their market value is exposed to a lot of different factors such as the operational and financial conditions of the relevant company, growth prospects, change in interest rates, the economic and political environment, foreign exchange rates, shifts in market sentiments etc. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. Past performance is not a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. When investing in individual shares, the investor may lose all or part of the investments.

Conflicts of interest

Readers of this document should note that Nordea Markets or Equity Sales & Research has received remuneration from the company mentioned in this document for the production of the report. The remuneration is not dependent on the content of the report. Nordea, affiliates or staff in Nordea, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the report.

To limit possible conflicts of interest and counter the abuse of inside knowledge, the analysts of Nordea Markets and Equity Sales & Research are subject to internal rules on sound ethical conduct, the management of inside information, handling of unpublished research material, contact with other units of Nordea and personal account dealing. The internal rules have been prepared in accordance with applicable legislation and relevant industry standards. The object of the internal rules is for example to ensure that no analyst will abuse or cause others to abuse confidential information. It is the policy of Nordea that no link exists between revenues from capital markets activities and individual analyst remuneration. Nordea and the branches are members of national stockbrokers' associations in each of the countries in which Nordea has head offices. Internal rules have been developed in accordance with recommendations issued by the stockbrokers associations. This material has been prepared following the Nordea Conflict of Interest Policy, which may be viewed at www.nordea.com/mifid.

Please find a list of all recommendations disseminated by Nordea Equities during the preceding 12-month period here: <https://research.nordea.com/compliance>

Distribution restrictions

The securities referred to in this report may not be eligible for sale in some jurisdictions. This report is not intended for, and must not be distributed to private customers in the UK or the US or to customers in any other jurisdiction where restrictions may apply.

This research report has not been prepared for distribution outside the EU, the UK or the US. The content of this research report is not a product disclosure statement or other regulated document for the purposes of the Australian Corporations Act 2001 (CTH). The distribution of this research report in Australia has not been authorised by any regulatory authority in Australia, and Nordea bank Abp is not licensed by the Australian Securities and Investment Commission to provide financial services in Australia.

This publication or report may be distributed in the UK to institutional investors by Nordea Bank Abp London Branch of 6th Floor, 5 Aldermanbury Square, London, EC2V 7AZ, which is under supervision of the European Central Bank, Finanstilsynet (Financial Supervisory Authority) in Finland and subject to limited regulation by the Financial Conduct Authority and Prudential Regulation Authority in the United Kingdom. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available upon request.

Nordea Bank Abp ("Nordea") research is not "globally branded" research. Nordea research reports are intended for distribution in the United States solely to "major U.S. institutional investors," as defined in Rule 15a-6 under the Securities Exchange Act of 1934. Any transactions in securities discussed within the research reports will be chaperoned by Nordea Securities LLC ("Nordea Securities"), an affiliate of Nordea and a SEC registered broker dealer and member of FINRA. Nordea Securities does not employ research analysts and has no contractual relationship with Nordea that is reasonably likely to inform the content of Nordea research reports. Nordea makes all research content determinations without any input from Nordea Securities.

The research analyst(s) named on this report are not registered/qualified as research analysts with FINRA. Such research analyst(s) are also not registered with Nordea Securities and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This report may not be mechanically duplicated, photocopied or otherwise reproduced, in full or in part, under applicable copyright laws.

Analyst Shareholding

Nordea analysts do not hold shares in the companies that they cover.
No holdings or other affiliations by analysts or associates.

Fair value and sensitivity

We calculate our fair values by weighting DCF, DDM, SOTP, asset-based and other standard valuation methods. Our fair values are sensitive to changes in valuation assumptions, of which growth, margins, tax rates, working capital ratios, investment-to-sales ratios and cost of capital are typically the most sensitive. It should be noted that our fair values would change by a disproportionate factor if changes are made to any or all valuation assumptions, owing to the non-linear nature of the standard valuation models applied (mentioned above). As a consequence of the standard valuation models we apply, changes of 1-2 percentage points in any single valuation assumption can change the derived fair value by as much as 30% or more. All research is produced on an ad hoc basis and will be updated when the circumstances require it.

Marketing Material

This research report should be considered marketing material, as it has been commissioned and paid for by the subject company, and has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report. However, Nordea Markets analysts are according to internal policies not allowed to hold shares in the companies/sectors that they cover.

Market-making obligations and other significant financial interest

Nordea has no market-making obligations in Atria shares.

As of 18/07/2024, Nordea Abp holds no positions of 0.5% or more of shares issued by Atria.

As of the publication of this report, the issuer does not hold a position exceeding 5% of the total shares issued in Nordea Abp.

Investment banking transactions and/or services

In view of Nordea's position in its markets, readers should assume that the bank may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking and/or ancillary services to the company/ companies.

Issuer Review

This report has not been reviewed by the Issuer prior to publication.

Completion Date

19 Jul 2024, 01:19 CET

Nordea Bank Abp	Nordea Bank Abp, filial i Sverige	Nordea Danmark, Filial af Nordea Bank Abp, Finland	Nordea Bank Abp, filial i Norge
Nordea IB & Equity Division, Equity Research Visiting address: Aleksis Kiven katu 7, Helsinki FI-00020 Nordea Finland	Nordea IB & Equity Division, Equity Research Visiting address: Smålandsgatan 17 SE-105 71 Stockholm Sweden	Nordea IB & Equity Division, Equity Research Visiting address: Grønjordsvej 10 DK-2300 Copenhagen S Denmark	Nordea IB & Equity Division, Equity Research Visiting address: Essendropsgate 7 N-0107 Oslo Norway
Tel: +358 9 1651 Fax: +358 9 165 59710	Tel: +46 8 614 7000 Fax: +46 8 534 911 60	Tel: +45 3333 3333 Fax: +45 3333 1520	Tel: +47 2248 5000 Fax: +47 2256 8650
Reg.no. 2858394-9 Satamaradankatu 5 Helsinki			